Due to the higher costs of PCSK9-inhibiting antibodies, reimbursement is limited to patients following myocardial infarction and (1) recurrent myocardial infarction; (2) diabetes mellitus; (3) documented statin intolerance; or (4) in patients with FH not reaching LDL‐C target levels despite statin/ezetimibe combination therapy. Here, PCSK9 is linked to myocardial infarction.